Research programme: scaffolding kinase-degradation therapeutics - Kymera Therapeutics
Latest Information Update: 15 Jan 2024
At a glance
- Originator Kymera Therapeutics
- Class Anti-inflammatories; Antipsoriatics; Small molecules
- Mechanism of Action Proteolysis
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Inflammatory bowel diseases; Lupus nephritis; Psoriasis
Most Recent Events
- 05 Dec 2023 Preclinical trials in Inflammatory bowel diseases in USA (unspecified route) (Kymera Therapeutics pipeline; December 2023)
- 05 Dec 2023 Preclinical trials in Lupus nephritis in USA (unspecified route) (Kymera Therapeutics pipeline; December 2023)
- 05 Dec 2023 Preclinical trials in Psoriasis in USA (unspecified route) (Kymera Therapeutics pipeline; December 2023)